

# Gulen Hatemi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3330298/gulen-hatemi-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

123  
papers

3,608  
citations

29  
h-index

57  
g-index

148  
ext. papers

4,660  
ext. citations

4.9  
avg, IF

5.41  
L-index

#	Paper	IF	Citations
123	F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging Appearance of Gastrointestinal Behçet's Disease.. <i>Molecular Imaging and Radionuclide Therapy</i> , <b>2022</b> , 31, 57-59	0.8	
122	Takayasu arteritis. <i>Current Opinion in Rheumatology</i> , <b>2022</b> , 34, 18-24	5.3	1
121	A treat-to-target approach is needed for Behçet's syndrome. <i>Current Opinion in Rheumatology</i> , <b>2022</b> , 34, 39-45	5.3	1
120	The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet's syndrome. <i>Rheumatology International</i> , <b>2021</b> , 1	3.6	4
119	Global epidemiology of vasculitis. <i>Nature Reviews Rheumatology</i> , <b>2021</b> ,	8.1	9
118	COVID-19 Among Patients With Inflammatory Rheumatic Diseases. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 651715	8.4	6
117	Screening for latent tuberculosis before starting TNF-alpha inhibitors in a population with high BCG vaccination rates. <i>Rheumatology International</i> , <b>2021</b> , 1	3.6	2
116	Recent Insights into the Management of Behçet Syndrome. <i>Journal of Inflammation Research</i> , <b>2021</b> , 14, 3429-3441	4.8	1
115	Aortic involvement in relapsing polychondritis: case-based review. <i>Rheumatology International</i> , <b>2021</b> , 41, 827-837	3.6	1
114	An evaluation of apremilast for the treatment of adult patients with oral ulcers associated with Behçet's syndrome. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 1533-1537	4	1
113	Behçet syndrome. <i>Nature Reviews Disease Primers</i> , <b>2021</b> , 7, 67	51.1	6
112	One year in review 2021: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 132, 3-13	2.2	
111	Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 132, 80-87	2.2	
110	One year in review 2021: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 3-13	2.2	4
109	Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 80-87	2.2	1
108	How to treat myelodysplastic syndrome with clinical features resembling Behçet syndrome: a case-based systematic review. <i>Annals of Hematology</i> , <b>2020</b> , 99, 1193-1203	3	7
107	Comment on: Clinical course of acute deep vein thrombosis of the legs in Behçet's syndrome: reply. <i>Rheumatology</i> , <b>2020</b> , 59, 914-915	3.9	

106	Disease course and healthcare costs of a cohort of rheumatoid arthritis patients from Turkey. <i>Rheumatology International</i> , <b>2020</b> , 40, 1037-1044	3.6	0
105	Disease Assessment in Behçet Syndrome <b>2020</b> , 261-278		1
104	A Few Suggestions for Further Research <b>2020</b> , 315-319		
103	Behçet Syndrome and Microbes <b>2020</b> , 191-199		1
102	Long term follow-up of Behçet's syndrome patients treated with cyclophosphamide. <i>Rheumatology</i> , <b>2020</b> , 59, 2264-2271	3.9	11
101	The OMERACT Core Set of Domains for Outcome Measures in Behçet Syndrome. <i>Arthritis Care and Research</i> , <b>2020</b> ,	4.7	7
100	Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 618973	8.4	2
99	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 19-30	2.4	270
98	Clinical course of acute deep vein thrombosis of the legs in Behçet's syndrome. <i>Rheumatology</i> , <b>2020</b> , 59, 799-806	3.9	13
97	One year in review 2020: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 127, 3-10	2.2	6
96	Update on the treatment of Behçet's syndrome. <i>Internal and Emergency Medicine</i> , <b>2019</b> , 14, 661-675	3.7	24
95	Behçet's Syndrome as a Model of Thrombo-Inflammation: The Role of Neutrophils. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1085	8.4	43
94	Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 1198-1201	4.1	4
93	Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 48, 752-762	5.3	38
92	Trial of Apremilast for Oral Ulcers in Behçet's Syndrome. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 1918-1928	59.2	65
91	THU0303 THE OMERACT CORE DOMAIN SET FOR CLINICAL TRIALS IN BEHÇET'S SYNDROME <b>2019</b> ,		2
90	Treating the Different Phenotypes of Behçet's Syndrome. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2830	8.4	22
89	Management of large-vessel vasculitis. <i>Current Opinion in Rheumatology</i> , <b>2019</b> , 31, 25-31	5.3	9

88	Tapering tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective study. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 122, 8	2.2	1
87	Patients' experiences with Behçet's syndrome: structured interviews among patients with different types of organ involvement. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 121, 28-34	2.2	3
86	Acknowledged statistical help and a better use of p values: a proposal. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 855-857	2.2	
85	Bone marrow oedema on sacroiliac/spine MRI: is it really a sign of objective inflammation warranting treatment?. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 122, 10	2.2	
84	The improper use of a no-treatment group in the randomised surgical trial for subacromial shoulder pain. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 122, 9	2.2	
83	Biosimilar infliximab for Behçet's syndrome: a case series. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 121, 111-115	2.2	3
82	One year in review 2019: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 121, 3-17	2.2	9
81	2018 update of the EULAR recommendations for the management of Behçet's syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 808-818	2.4	277
80	Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies. <i>Rheumatology International</i> , <b>2018</b> , 38, 607-622 <sup>3.6</sup>		6
79	Behçet syndrome: a contemporary view. <i>Nature Reviews Rheumatology</i> , <b>2018</b> , 14, 107-119	8.1	167
78	Biomarkers in vasculitis. <i>Current Opinion in Rheumatology</i> , <b>2018</b> , 30, 30-35	5.3	12
77	Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations. <i>Rheumatology</i> , <b>2018</b> , 57, 2200-2212	3.9	57
76	Assessing the possible association of anti-TNF use with new malignancies: A neglected methodological consideration. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 894-901	2.6	1
75	Gastrointestinal Involvement in Behçet Disease. <i>Rheumatic Disease Clinics of North America</i> , <b>2018</b> , 44, 45-64	2.4	32
74	Faecal but not serum calprotectin levels look promising in predicting active disease in Behçet's syndrome patients with gastrointestinal involvement. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 90-96	2.2	7
73	One year in review 2018: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 13-27	2.2	8
72	Systemic vasculitis and the gut. <i>Current Opinion in Rheumatology</i> , <b>2017</b> , 29, 33-38	5.3	13
71	Developing a Core Set of Outcome Measures for Behçet Disease: Report from OMERACT 2016. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1750-1753	4.1	18

70	Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study. <i>Medicine (United States)</i> , <b>2017</b> , 96, e7859	1.8	8
69	Apremilast for the treatment of Behçet's syndrome. <i>Expert Opinion on Orphan Drugs</i> , <b>2017</b> , 5, 677-681	1.1	2
68	Inadequate reporting of enrolled patient and study site characteristics, and inter-study site differences in randomized controlled trials: A systematic review in six leading medicine journals. <i>European Journal of Internal Medicine</i> , <b>2017</b> , 37, e34-e36	3.9	
67	Behçet's syndrome: providing integrated care. <i>Journal of Multidisciplinary Healthcare</i> , <b>2017</b> , 10, 309-319	2.8	22
66	Method. <i>Turkish Journal of Gastroenterology</i> , <b>2017</b> , 28, S3	1	
65	Behçet's disease: an MHC-I-opathy?. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 104, 5	2.2	4
64	One year in review 2017: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 108, 3-15	2.2	9
63	Infliximab for uveitis of Behçet's syndrome: a trend for earlier initiation. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 108, 86-89	2.2	8
62	Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 524-9	4.1	58
61	Recommendations in the American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Related to the Use of Biologic Agents in Patients With a History of Cancer Need Reconsideration: Comment on the Article by Singh et al. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 724	4.7	1
60	Management of Behçet's syndrome. <i>Current Opinion in Rheumatology</i> , <b>2016</b> , 28, 45-50	5.3	18
59	Recommendations in the American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Related to the Use of Biologic Agents in Patients With a History of Cancer Need Reconsideration: Comment on the Article by Singh et al. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1315-6	9.5	2
58	Diagnostic Criteria as Separate From Classification Criteria: A Perpetual Motion Machine? Comment on the Article by Aggarwal et al. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 1049	4.7	1
57	Characteristics, Treatment, and Long-Term Outcome of Gastrointestinal Involvement in Behçet's Syndrome: A Strobe-Compliant Observational Study From a Dedicated Multidisciplinary Center. <i>Medicine (United States)</i> , <b>2016</b> , 95, e3348	1.8	52
56	Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy. <i>Rheumatology International</i> , <b>2016</b> , 36, 1719-1725	3.6	15
55	One year in review 2016: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 10-22	2.2	12
54	Pulmonary artery involvement in Behçet's syndrome: Effects of anti-Tnf treatment. <i>Seminars in Arthritis and Rheumatism</i> , <b>2015</b> , 45, 369-73	5.3	46
53	Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1510-8	59.2	157

52	Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 2436-41	4.1	14
51	Development of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) and brain tumor in a patient after more than 7 years of omalizumab use: A case report. <i>International Journal of Immunopathology and Pharmacology</i> , <b>2015</b> , 28, 134-7	3	3
50	Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 2465-9	4.1	26
49	Ocular Involvement of Behçet's Syndrome: a Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2015</b> , 49, 298-306	12.3	36
48	Currently Used Biologic Agents in the Management of Behçet's Syndrome. <i>Current Medicinal Chemistry</i> , <b>2015</b> , 22, 1976-85	4.3	5
47	Double pylorus in a patient with Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S138-40	2.2	6
46	A reappraisal of the association between Behçet's disease, myelodysplastic syndrome and the presence of trisomy 8: a systematic literature review. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S145-51	2.2	18
45	Suicidal ideation among patients with Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S30-5	2.2	5
44	TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S129-37	2.2	23
43	Fatigue is correlated with disease activity but not with the type of organ involvement in Behçet's syndrome: a comparative clinical survey. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S107-12	2.2	8
42	Behçet's syndrome: a critical digest of the 2014-2015 literature. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S3-14	2.2	62
41	Current status of outcome measure development in vasculitis. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 593-84.1	4.1	25
40	No appreciable decrease in fertility in Behçet's syndrome. <i>Rheumatology</i> , <b>2014</b> , 53, 828-33	3.9	16
39	Outcome measures used in clinical trials for Behçet syndrome: a systematic review. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 599-612	4.1	41
38	Behçet syndrome manifestations and activity in the United States versus Turkey -- a cross-sectional cohort comparison. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1379-84	4.1	34
37	Turkish PASE: Turkish Version of the Psoriatic Arthritis Screening and Evaluation Questionnaire. <i>Annals of Dermatology</i> , <b>2014</b> , 26, 457-61	0.4	4
36	Biologics, colchicine, corticosteroids, immunosuppressants and interferon-alpha for Neuro-Behçet's Syndrome. <i>The Cochrane Library</i> , <b>2014</b> , CD010729	5.2	7
35	Novel NLRP3/cryopyrin mutations and pro-inflammatory cytokine profiles in Behçet's syndrome patients. <i>International Immunology</i> , <b>2014</b> , 26, 71-81	4.9	23

34	Colchicine in Behçet syndrome: a longterm survey of patients in a controlled trial. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 735-8	4.1	12
33	Management of Behçet's syndrome. <i>Current Opinion in Rheumatology</i> , <b>2014</b> , 26, 285-91	5.3	10
32	Bone marrow transplantation for Behçet's disease: a case report and systematic review of the literature. <i>Rheumatology</i> , <b>2014</b> , 53, 1136-41	3.9	29
31	Behçet's syndrome: a critical digest of the 2013-2014 literature. <i>Clinical and Experimental Rheumatology</i> , <b>2014</b> , 32, S112-22	2.2	39
30	Behçet's syndrome. <i>Rheumatic Disease Clinics of North America</i> , <b>2013</b> , 39, 245-61	2.4	75
29	Lack of efficacy of tocilizumab in mucocutaneous Behcet's syndrome: report of two cases. <i>Rheumatology</i> , <b>2013</b> , 52, 1923-4	3.9	38
28	Sexual dysfunction and depression in premenopausal women with mucocutaneous Behçet's disease. <i>International Journal of Rheumatic Diseases</i> , <b>2013</b> , 16, 463-8	2.3	6
27	Behçet's syndrome: a critical digest of the 2012-2013 literature. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, 108-17	2.2	7
26	Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists. <i>Arthritis Research and Therapy</i> , <b>2012</b> , 14, R147	5.7	21
25	The papulopustular lesion/arthritis cluster of Behçet's syndrome also clusters in families. <i>Rheumatology</i> , <b>2012</b> , 51, 1053-60	3.9	26
24	Who are the young professionals working in the field of rheumatology in Europe and what are their needs? An EMEUNET (EMerging EUlar NETwork) survey. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1432-3	2.4	7
23	Canakinumab in a patient with juvenile Behcet's syndrome with refractory eye disease. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1589-91	2.4	80
22	JAK2 (V617F) mutation is not associated with thrombosis in Behcet syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2012</b> , 18, 421-6	3.3	2
21	Pulmonary artery involvement and associated lung disease in Behçet disease: a series of 47 patients. <i>Medicine (United States)</i> , <b>2012</b> , 91, 35-48	1.8	112
20	Should maintenance therapy be performed in ulcerative proctitis? How long should it be continued?. <i>Turkish Journal of Gastroenterology</i> , <b>2012</b> , 23 Suppl 2, 21-4	1	2
19	Do anti-TNF agents and combination treatment increase postoperative complication risk?. <i>Turkish Journal of Gastroenterology</i> , <b>2012</b> , 23 Suppl 2, 25-9	1	
18	Behçet's syndrome and micro-organisms. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2011</b> , 25, 389-406	5.3	27
17	Analysis of MEFV exon methylation and expression patterns in familial Mediterranean fever. <i>BMC Medical Genetics</i> , <b>2011</b> , 12, 105	2.1	25

16	Prognosis of Behcet's syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial. <i>Rheumatology</i> , <b>2010</b> , 49, 173-7	3.9	28
15	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1744-50	2.4	114
14	Analyses of functional IL10 and TNF- $\beta$ genotypes in Behçet's syndrome. <i>Molecular Biology Reports</i> , <b>2010</b> , 37, 3637-41	2.8	17
13	Reply to letter by Priori et al commenting on whether Behçet's syndrome patients with acne and arthritis comprise a true subset. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 305-6		11
12	Locomotor System Disease in Behçet Syndrome <b>2010</b> , 149-163		1
11	Genetic susceptibility to Behçet's syndrome is associated with NRAMP1 (SLC11A1) polymorphism in Turkish patients. <i>Rheumatology International</i> , <b>2009</b> , 29, 787-91	3.6	9
10	Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 1528-34	2.4	131
9	Atherosclerosis in Behçet's Syndrome. <i>Seminars in Arthritis and Rheumatism</i> , <b>2008</b> , 38, 1-12	5.3	63
8	Increased enthesopathy among Behçet's syndrome patients with acne and arthritis: an ultrasonography study. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 1539-45		78
7	EULAR recommendations for the management of Behçet disease. <i>Annals of the Rheumatic Diseases</i> , <b>2008</b> , 67, 1656-62	2.4	478
6	Tumor necrosis factor-alpha and interleukin-10 gene promoter polymorphisms in Turkish rheumatoid arthritis patients. <i>Clinical Rheumatology</i> , <b>2008</b> , 27, 1243-8	3.9	33
5	Increased serum sialic acid levels in primary osteoarthritis and inactive rheumatoid arthritis. <i>Tohoku Journal of Experimental Medicine</i> , <b>2007</b> , 213, 241-8	2.4	19
4	Infliximab does not suppress the tuberculin skin test (purified protein derivative). <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 474-80	4.1	17
3	Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma. <i>Annals of Hematology</i> , <b>2005</b> , 84, 609-13	3	21
2	Necrotizing vasculitis associated with familial Mediterranean fever. <i>American Journal of Medicine</i> , <b>2004</b> , 117, 516-9	2.4	16
1	Bilateral inflammatory breast metastases of epithelial ovarian cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1999</b> , 22, 408-10	2.7	28